PAR Inc.
Cross-source consensus on PAR Inc. from 1 sources and 3 claims.
1 sources · 3 claims
Interactions
Where it comes from
Highlighted claims
- PAR Inc. requested the added paragraph concerning use of the Chinese MMSE. — Correction: ‘SinoMAKS—protocol of a randomised controlled trial to evaluate the Chinese version of the non-pharmacological, multimodal MAKS intervention for people with mild to moderate dementia in Chinese nursing homes’
- PAR is identified as the relevant rights organisation for the MMSE. — Correction: ‘SinoMAKS—protocol of a randomised controlled trial to evaluate the Chinese version of the non-pharmacological, multimodal MAKS intervention for people with mild to moderate dementia in Chinese nursing homes’
- The practical significance of the correction is rights-related because it documents that the Chinese MMSE required authorisation from PAR. — Correction: ‘SinoMAKS—protocol of a randomised controlled trial to evaluate the Chinese version of the non-pharmacological, multimodal MAKS intervention for people with mild to moderate dementia in Chinese nursing homes’